# MYALEPTA®▼

(metreleptin powder for solution for injection)

## DOSE AND PRESCRIBING INFORMATION: SPECIALIST PRESCRIBER GUIDE

This brochure should be read in conjunction with the Summary of Product Characteristics.[1]

myalepta® metreleptin

Adverse events should be reported. Reporting forms and information can be found at Yellow Card Scheme Website: **www.mhra.gov.uk/yellowcard** or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to Amryt by email to **medinfo@amrytpharma.com** or by telephoning the free phone number **00 800 4447 4447**.

**Date of preparation August 2021** C-MTA/UK/0040

AMRYT PHARMA

# Table of contents



# Introduction

This brochure is for Specialist Prescribers at the National Specialist Service at Addenbrooke's Hospital in Cambridge, which is the only centre in the UK for the treatment of people with lipodystrophy.

Myalepta is provided as a powder for solution for injection for administration subcutaneously. Following treatment initiation, Myalepta is to be self-administered by the patient or carer on a daily basis at home. It is important that the specialist healthcare professionals provide patients and carers with training on the reconstitution of the product and proper subcutaneous injection technique, so as to avoid intramuscular injection in patients with minimal subcutaneous adipose tissue.

The brochure provides information on:

- Determining the right dose of Myalepta
- Training the patient to prepare and inject Myalepta
- Prescribing Myalepta and the required ancillary items

**The brochure should be read in conjunction with the Summary of Product Characteristics (SmPC)[1] and with the brochure on Important Risk Minimisation Information: Guide for Healthcare Professionals.**

# Therapeutic Indications

Myalepta is indicated as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy patients:[1]

- With confirmed congenital generalised lipodystrophy (Berardinelli-Seip syndrome) or acquired generalised lipodystrophy (Lawrence syndrome) in adults and children 2 years of age and above
- With confirmed familial partial lipodystrophy or acquired partial lipodystrophy (Barraquer-Simons syndrome), in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control

**Treatment with Myalepta (metreleptin) should be initiated and monitored by a physician experienced in the diagnosis and management of metabolic disorders.**

## Important advice to patients on risk minimisation

Healthcare professionals should advise patients about the key risks associated with Myalepta. These are detailed in the brochure on Important Risk Minimisation Information: Guide for Healthcare Professionals and the guide for patients and their carers (Patient Care Guide: Important Risk Minimisation Information for Patients and their Carers).

**They include:**

- Hypoglycaemia with concomitant use of insulin and other anti-diabetics.
- Acute pancreatitis associated with abrupt discontinuation of Myalepta.
- Unplanned pregnancy due to improvement of hormonal dysfunction with Myalepta.
- Autoimmune disorder progression.
- Medication errors.
- Serious and severe infections or loss of efficacy secondary to neutralising antibodies despite adherence to Myalepta administration.
- T-cell lymphomas.
- Hypersensitivity.

## Determining the right dose of Myalepta

The recommended daily dose of Myalepta is based on body weight and gender as provided in Table 1.

- In order to ensure patients and carers understand the correct dose to be injected, **the prescriber should prescribe the appropriate dose both in milligrams (mg) and the volume in millilitres (mL).**[1]
- In order to avoid medication errors including overdose, the dose calculation and dose adjustment guidelines below should be followed.[1]
- Actual body weight at initiation of treatment should always be used when calculating the dose of Myalepta.[1]

**Table 1: Myalepta recommended dose[1]**

| Baseline weight | Starting daily dose (injection volume) | Dose adjustments (injection volume) | Maximum daily dose (injection volume) |
|---|---|---|---|
| Males and females ≤ 40 kg | 0.06 mg/kg (0.012 mL/kg) | 0.02 mg/kg (0.004 mL/kg) | 0.13 mg/kg (0.026 mL/kg) |
| Males > 40 kg | 2.5 mg (0.5 mL) | 1.25 to 2.5 mg (0.25 to 0.5 mL) | 10 mg (2 mL) |
| Females > 40 kg | 5 mg (1 mL) | 1.25 to 2.5 mg (0.25 to 0.5 mL) | 10 mg (2 mL) |

The starting dose calculator is shown in Table 2.

**Table 2: Dose calculation[1]**

| Weight and gender | Starting dose calculation |
|---|---|
| Males and females ≤ 40 kg once daily dose | Weight (kg) x 0.06 mg/kg = Individual patient daily starting dose in mg<br>Weight (kg) x 0.012 mL/kg = Individual patient daily starting volume to inject in mL<br>**Example:**<br>25 kg patient is initiated at 0.06 mg/kg of Myalepta. The individual patient dose = 1.5 mg<br>25 kg patient is initiated at 0.012 mL/kg = 0.3 mL of Myalepta solution to inject |
| Males > 40 kg once daily dose | Individual patient once daily dose in mg = 2.5 mg<br>Amount to inject once daily dose = 0.5 mL |
| Females > 40 kg once daily dose | Individual patient once daily dose in mg = 5 mg<br>Amount to inject once daily dose = 1 mL |

Dose adjustments should be made as described in the SmPC,[1] which also includes a dose increase calculator.

### For doses of Myalepta ≤ 1.5 mg (0.3 mL)

If the prescribed dose of Myalepta is ≤ 1.5 mg (0.3 mL) the dose will also have to be prescribed in Units. This is because the patient will need to use the U100 insulin syringe to inject it. A dose conversion chart is provided in Table 3 below.

**Table 3: Conversion of dose to units with U100 0.3 mL syringe**

| Weight of child | Dose of Myalepta | Actual amount of solution* | Rounded amount of solution | 'Unit' measurement volume in 0.3 mL syringe to inject |
|---|---|---|---|---|
| 9 kg | 0.54 mg | 0.108 mL | 0.10 mL | 10 |
| 10 kg | 0.60 mg | 0.120 mL | 0.12 mL | 12 |
| 11 kg | 0.66 mg | 0.132 mL | 0.13 mL | 13 |
| 12 kg | 0.72 mg | 0.144 mL | 0.14 mL | 14 |
| 13 kg | 0.78 mg | 0.156 mL | 0.15 mL | 15 |
| 14 kg | 0.84 mg | 0.168 mL | 0.16 mL | 16 |
| 15 kg | 0.90 mg | 0.180 mL | 0.18 mL | 18 |
| 16 kg | 0.96 mg | 0.192 mL | 0.19 mL | 19 |
| 17 kg | 1.02 mg | 0.204 mL | 0.20 mL | 20 |
| 18 kg | 1.08 mg | 0.216 mL | 0.21 mL | 21 |
| 19 kg | 1.14 mg | 0.228 mL | 0.22 mL | 22 |
| 20 kg | 1.20 mg | 0.240 mL | 0.24 mL | 24 |
| 21 kg | 1.26 mg | 0.252 mL | 0.25 mL | 25 |
| 22 kg | 1.32 mg | 0.264 mL | 0.26 mL | 26 |
| 23 kg | 1.38 mg | 0.276 mL | 0.27 mL | 27 |
| 24 kg | 1.44 mg | 0.288 mL | 0.28 mL | 28 |
| 25 kg | 1.50 mg | 0.300 mL | 0.30 mL | 30 |

*Note: Initial and dose increments should be rounded down to the nearest 0.01 mL

## Dose Cards

Patients should be provided with their daily dosage both in mg and mL and, if the dose is ≤1.5 mg (0.3 mL) and the 0.3 mL U100 insulin syringe is used, the equivalent units. Patients and/or carers should be given Dose Cards, completed with their daily dosage, to take home with them. Your Specialist Centre will have been given copies of these Dose Cards.



## Training the patient to prepare and inject Myalepta

The first injection of Myalepta should always be supervised by a healthcare professional and it is important that the patient and/or carer is appropriately trained before self-administering Myalepta at home.[1] Information and training on the administration of Myalepta will initially be provided to the patient and/or carer at the Specialist Service at Addenbrooke's Hospital. A Homecare Nurse will then support the patient and/or carer in their initial self-administration of Myalepta at home. A follow-up of injection technique should be performed six-monthly when the patient visits the Specialist Service.[1]

Myalepta should be administered subcutaneously at approximately the same time every day.[1] It can be administered any time of the day without regard to the timing of meals. If the patient misses a dose, Myalepta should be administered as soon as the omission is noticed, and the normal dosing schedule resumed the next day.[1]

### IMPORTANT:

- Myalepta should be stored in a refrigerator.
- Keep the vial in the outer carton in order to protect from light.
- The administration kits are to be stored at room temperature.
- After reconstitution, the solution must be administered immediately and cannot be stored for later use.
- One vial of Myalepta and one vial/ampoule of water for injection must therefore be prescribed per day and the patient instructed to dispose of any unused medicine and unused water immediately after injection.
- The smallest appropriate size of water for injection (5 mL or less) should be prescribed to reduce the risk of re-use.

## Other measures to support risk minimisation

Amryt has initiated a programme of educational activities including a brochure on Important Risk Minimisation Information: Guide for Healthcare Professionals and a brochure for patients and their carers (Patient Care Guide: Important Risk Minimisation Information for Patients and their Carers).

In addition, information on correct preparation and injection techniques, in the form of an Instructions for Use guide are provided in the Package Leaflet contained in every pack of Myalepta. Additionally, a Patient Instruction Video demonstrating the correct preparation and injection technique for the prescribed dose is also available and can be accessed using the QR Code at the bottom of the page or through the Myalepta RMP website at www.myaleptainfo.eu.

The Patient Care Guide (Patient Care Guide: Important Risk Minimisation Information for Patients and their Carers) and the Dose Cards should be provided to every patient. Your Centre will have been given copies of these to distribute. Further supplies of these and all other educational materials are available from Amryt or can be downloaded from the Myalepta RMP website at www.myaleptainfo.eu.

# Prescribing Myalepta and the required ancillary items

Supplies of Myalepta and the ancillary items to reconstitute and administer Myalepta will be provided to the patient's home using a Home Care Delivery Service.

## MYALEPTA

Myalepta is available in 3 vial sizes:

- Myalepta 3 mg powder for solution for injection: Each vial contains 3 mg of metreleptin. After reconstitution with 0.6 mL water for injections, each mL contains 5 mg of metreleptin.
- Myalepta 5.8 mg powder for solution for injection: Each vial contains 5.8 mg of metreleptin. After reconstitution with 1.1 mL water for injections, each mL contains 5 mg of metreleptin.
- Myalepta 11.3 mg powder for solution for injection: Each vial contains 11.3 mg of metreleptin. After reconstitution with 2.2 mL water for injections, each mL contains 5 mg of metreleptin.

## PRESCRIBING ANCILLARY ITEMS TO RECONSTITUTE AND ADMINISTER MYALEPTA

For ease of prescribing and to reduce the risk of medication errors, Amryt will supply reconstitution and administration kits to the patients as indicated in Table 4. They will be provided to the patient's home using a Home Care Delivery Service. The quantities in each kit will support a 30-vial pack of Myalepta.

**Table 4: Administration kits**

| Kit name | Contents |
|---|---|
| Myalepta reconstitution kit for 11.3 mg and 5.8 mg vials | 30 x 3 mL syringes<br>30 needles 21 G x 40 mm<br>60 alcohol swabs |
| Myalepta reconstitution kit for 3 mg vials | 30 x 1 mL syringes<br>30 needles 21 G x 40 mm<br>60 alcohol swabs |
| Myalepta administration kit for doses > 5 mg (1.0 mL) | 30 x 2.5 mL syringe<br>30 needles 30 G x 13 mm |
| Myalepta administration kit for doses > 1.5 mg (0.3 mL) to 5 mg (1.0 mL) | 30 x 1.0 mL syringe<br>30 needles 30 G x 13 mm |
| Myalepta administration kit for doses ≤ 1.5 mg (0.3 mL) | 30 x 0.3 mL U100 insulin syringe with integrated 31 G x 8 mm needle |

### For doses of Myalepta ≤ 1.5 mg (0.3 mL)

Please note that to deliver a dose of Myalepta ≤ 1.5 mg (0.3 mL), the Amryt administration kit will include a Beckton Dickinson 305937 SafetyGlide Safety Insulin (U100) Syringe 0.3 mL with 31 G x 8 mm needle, as insulin syringes are the only commercially available ones suited to accurate dosing up to 0.3 mL.

## Entering patients into the Myalepta patient registry

Amryt has committed, as a condition of its marketing authorisation for Myalepta in the EU, to establish a registry including all patients with generalised or partial lipodystrophy treated with Myalepta according to an agreed protocol. This registry will further evaluate the longterm safety and effectiveness of Myalepta under normal conditions of clinical practice. Participation in the registry should be offered to all eligible patients. Patients should be reassured that all data that is collected will be anonymised.

Please contact medinfo@amrytpharma.com for further information about the registry and your participation.

## References

1. Amryt Pharmaceuticals. Myalepta Summary of Product Characteristics, available at https://www.medicines.org.uk/emc/product/11183/smpc

Amryt Pharmaceuticals DAC
45 Mespil Road
Dublin 4
Ireland

Phone: 00 800 4447 4447
Email: medinfo@amrytpharma.com